Swelling improver and cosmetic

Abstract

One embodiment of a swelling improver according to the present disclosure contains 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active component.

Description

Swelling reducing agents and cosmetics

[0001] The present invention relates to an anti-puffiness agent and a cosmetic.

[0002] The cutaneous vascular system exists in the dermis and is composed of blood vessels and lymphatic vessels. To maintain homeostasis, tissue fluid that has moved out of the blood vessels must return to the veins. Skin veins efficiently deliver blood flow to the central nervous system. However, veins themselves have little ability to take in tissue fluid. For this reason, it has been understood that tissues that take in tissue fluid, namely lymphatic vessels, are essential structures in the skin.

[0003] Lymphatic vessels play an important role in maintaining a constant microenvironment around cells by collecting waste materials in the skin and water and proteins that constantly leak from blood vessels. When water and other substances that have leaked out of blood vessels are no longer smoothly collected into veins or lymphatic fluid, and more than necessary accumulates between cells, this condition is commonly known as "edema."

[0004] For example, swelling of the face when waking up or swelling of the legs when tired is not only unhealthy but also a major enemy of beauty. Furthermore, if this swelling is left untreated, it can cause pressure on surrounding blood vessels, further worsening the swelling and leading to pathological swelling.

[0005] Conventionally, methods for eliminating swelling have been to improve circulation of blood and lymph by massage or the like, and to facilitate smooth excretion of water. Furthermore, drugs, plant extracts, and the like are considered effective for reducing swelling. For example, there are an agent for reducing swelling containing α-glycosylated rutin as an active ingredient (see Patent Document 1), an agent for reducing swelling containing α-glycosylated hesperidin as an active ingredient (see Patent Document 2), an agent for reducing swelling containing Poria cocos as an active ingredient (see Patent Document 3), an agent for reducing skin swelling containing one or more selected from extracts of plants belonging to the Bupleurum genus, extracts of plants belonging to the Coix genus, extracts of plants belonging to the Zea genus, and whey extracts (see Patent Document 4), an agent for reducing skin swelling containing one or more selected from extracts of plants belonging to the Acorus genus (Acorus calamus L.), extracts of plants belonging to the Acorus gramineus genus (Acorus gramineus L.), and extracts of plants belonging to the Acorus genus (Acorus gramineus L.). Solaris, etc.), the genus Hamamelis (Witch hazel (Hamamelis virginiana L.) etc.), the genus Citrus (Spruce (Citrus aurantium L.) etc.), the genus Zanthoxylum (Zanthoxylum piperitum L.DC.) etc.), the genus Carica (Papaya (Carica papaya L.) etc.), the genus Vitis (Vitis vinifera L.) etc.), the genus Thymus (Thymus serpyllum Patent Document 5 discloses a technique for reducing swelling, characterized by blending one or more extracts of plants belonging to the genus Pinus (Sylvestris L., etc.), the genus Pinus (Scots pine (Pinus sylvestris L.), etc.), the genus Salvia (Salvia splendens Sellow, etc.).

[0006] However, despite these many attempts, the swelling-reducing effect is not fully satisfactory, and there is a strong demand for the provision of an agent for reducing swelling that can more effectively reduce swelling.

[0007] Japanese Patent Laid-Open No. 10-182468 Japanese Patent Laid-Open No. 10-218777 Japanese Patent Laid-Open No. 2000-239138 Japanese Patent Laid-Open No. 2003-14739 Japanese Patent Laid-Open No. 2004-35425

[0008] In view of the above, an object of one aspect of the present invention is to provide an anti-edema agent that has an excellent effect of reducing edema.

[0009] In order to solve the above problems, one embodiment of the anti-edema agent according to the present invention is characterized in that it contains 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient.

[0010] According to one aspect of the present invention, an anti-edema agent having an excellent effect of reducing edema can be provided.

[0011] FIG. 1 is a diagram illustrating gravitational swelling for evaluating the swelling-reducing effect of an anti-edema agent according to one embodiment. FIG. 2 is a diagram illustrating gravitational depression for evaluating the swelling-reducing effect of an anti-edema agent according to one embodiment. FIG. 3A is a schematic explanatory diagram of a pair of left and right facial photographs in Test Example 1. FIG. 3B is a graph showing the results of visual assessment in Test Example 1. The vertical axis indicates the results of visual assessment, and the horizontal axis indicates the time when the visual assessment was performed. FIG. 4 is a graph showing the change in the amount of improvement in facial swelling (Sc) from week 0 to 6 weeks after the start of the test in Test Example 1. The vertical axis indicates the amount of improvement (cc) in the amount of swelling (Sc), and the horizontal axis indicates the test period (weeks).

[0012] Hereinafter, embodiments of the present invention will be described in detail. Note that the embodiments are not limited by the following description and can be modified as appropriate within the scope of the present invention. Furthermore, in this specification, unless otherwise specified, the term "to" indicating a range of values ​​means that the values ​​before and after it are included as the lower and upper limits.

[0013] (Anti-edema Agent) An anti-edema agent according to one embodiment contains 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient, and further contains other ingredients as necessary.

[0014] "Swelling" refers to a condition in which, for some reason, fluid in the blood leaks out of the blood vessels and accumulates abnormally in the skin or subcutaneous tissue. "Swelling" is also called "edema."

[0015] The method for confirming the swelling-reducing effect of the swelling-reducing agent according to one embodiment is not particularly limited and can be appropriately selected depending on the purpose. For example, if sensory evaluation reveals that swelling is reduced after application of the swelling-reducing agent compared to before application or when the swelling-reducing agent is not applied, it can be determined that the swelling-reducing agent has an effect of reducing swelling.

[0016] Alternatively, a method of checking for the presence or absence of swelling by finger pressure, which has traditionally been used to treat swelling in the limbs, particularly the feet, can also be used. Specifically, before applying an edema-reducing agent or when an edema-reducing agent is not being applied, the skin of the target area is pressed with the pad of a finger for 5 seconds, and the time from when the finger is released until the skin returns to its original state from a depressed state (hereinafter referred to as "T0") is measured. Next, after applying the edema-reducing agent, the skin of the target area to which the edema-reducing agent has been applied is pressed with the pad of a finger for 5 seconds, and the time from when the finger is released until the skin returns to its original state from a depressed state (hereinafter referred to as "T1") is measured. If T1 is shorter than T0, i.e., if (T1 - T0) is a positive value, it can be determined that the edema-reducing agent has an edema-reducing effect.

[0017] Furthermore, when checking facial swelling, the swelling-reducing effect can also be confirmed by the following quantitative method. Specifically, before or after application of the swelling-reducing agent to the subject, data representing the three-dimensional shape of the subject's face (hereinafter sometimes referred to as "three-dimensional facial image") is captured using a known three-dimensional image capture device. Three-dimensional facial images are obtained when the subject's face is in a horizontal position (specifically, when the facial midline is held at a right angle to the direction of gravity) and when the subject's face is in a vertical position (specifically, when the facial midline is held at a parallel position to the direction of gravity). Next, using a computer, the gravitational swelling amount (VCswelling) and gravitational depression amount (VCshrinking) shown below are calculated based on the change in three-dimensional shape between the three-dimensional facial image when the subject's face is in the horizontal position and the three-dimensional facial image when the subject's face is in the vertical position. Next, the amount of facial swelling (Sc) shown below is calculated based on the amount of gravitational swelling (VCswelling) and the amount of gravitational depression (VCshrinking). Similarly, after applying an anti-swelling agent to a subject, the amount of gravitational swelling (VCswelling), the amount of gravitational depression (VCshrinking), and the amount of facial swelling (Sc) are calculated from data representing the three-dimensional shape of the subject's face. Next, the amount of facial swelling (Sc) before applying the anti-swelling agent or when not applying the anti-swelling agent is compared with the amount of facial swelling (Sc) after applying the anti-swelling agent, thereby determining whether the anti-swelling agent has an effect of improving swelling.

[0018] Calculation of Gravitational Swelling (VCswelling) Figure 1 is a diagram for explaining gravitational swell according to one embodiment of the present invention. A three-dimensional facial image of a subject's face when it is in a horizontal position and a three-dimensional facial image of the subject when it is in a vertical position are acquired, and the three-dimensional shapes in the horizontal position and the vertical position are compared. The volume of the region within the dashed line in Figure 1 is larger in the vertical position. In this way, the three-dimensional shapes of the subject when it is in a horizontal position and the three-dimensional shapes when it is in a vertical position are compared, and the difference in volume between the two regions (i.e., the horizontal and vertical positions) for the regions with a larger volume in the vertical position is determined as the gravitational swell (VCswelling).

[0019] Calculation of Gravitational Depression (VC Shrinking) Figure 2 is a diagram for explaining gravity depression according to one embodiment of the present invention. A three-dimensional facial image of the subject's face when it is in a horizontal position and a three-dimensional facial image of the subject's face when it is in a vertical position are acquired, and the three-dimensional shapes in the horizontal position and the vertical position are compared. In this way, the difference in volume between the two regions (i.e., the horizontal and vertical positions) of the region that has a smaller volume in the vertical position of the subject is taken as the gravity depression (VC shrinking).

[0020] -Calculation of Facial Swelling Amount (Sc)- The facial swelling amount (Sc) can be calculated using the following formula (1).

[0021] (Note that in formula (1), "Sc" represents the amount of facial swelling, "VCswelling" represents the amount of gravitational swelling, and "VCshrinking" represents the amount of gravitational depression.)

[0022] If the amount of facial swelling before application of the swelling-reducing agent or when the swelling-reducing agent is not applied is "Sc0" and the amount of facial swelling after application of the swelling-reducing agent is "Sc1", the improvement in the amount of facial swelling (Sc) can be calculated using the following formula (2). If this improvement in the amount of facial swelling (Sc) is a positive value, it can be confirmed that the swelling-reducing agent has an effect of improving swelling. Furthermore, the larger the numerical value of the improvement in the amount of swelling (Sc), the better the swelling-reducing effect of the swelling-reducing agent. Furthermore, the swelling-reducing effect of the swelling-reducing agent can also be confirmed using the method described in the test examples below.

[0023] Improvement in facial swelling (Sc) = Sc0 - Sc1 ... Equation (2)

[0024] <1-(2-hydroxyethyl)-2-imidazolidinone or derivative thereof> There are no particular limitations on the 1-(2-hydroxyethyl)-2-imidazolidinone (hereinafter sometimes referred to as "HEI") or a derivative thereof, so long as it has an effect of reducing swelling, and can be appropriately selected depending on the purpose. However, a cyclic carboxamide derivative represented by the following general formula (1) or a salt thereof is preferred.

[0025] (In the general formula (1), n ​​represents an integer of 1 to 3, and R １ represents a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydrogen atom or a hydroxyl group, and X represents -CH ２ - or -N(R ２ )-, and R ２ represents a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydrogen atom or a hydroxyl group.

[0026] In the general formula (1), n ​​is an integer of 1 to 3, preferably an integer of 1 to 2, and more preferably an integer of 1.

[0027] In the general formula (1), R １ When is a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, the hydrocarbon group preferably has 1 to 4 carbon atoms, more preferably 1 to 3 carbon atoms, and even more preferably 2 carbon atoms.

[0028] In the general formula (1), X is —N(R ２ )-, R ２ is a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydrogen atom or a hydroxyl group, but is preferably a hydrogen atom.

[0029] Among the cyclic carboxamide derivatives represented by the general formula (1), the compound represented by the following structural formula (1) is 1-(2-hydroxyethyl)-2-imidazolidinone.

[0030]

[0031] The derivative of 1-(2-hydroxyethyl)-2-imidazolidinone is a compound other than the compound represented by the structural formula (1) in the cyclic carboxamide derivative represented by the general formula (1). The derivative of 1-(2-hydroxyethyl)-2-imidazolidinone is not particularly limited as long as it has an effect of reducing swelling, and can be appropriately selected depending on the purpose, but 2-imidazolidinone, which is a compound represented by the following structural formula (2), or 1-(2-hydroxyethyl)-2-pyrrolidone, which is a compound represented by the following structural formula (3), is preferred.

[0032]

[0033]

[0034] The salt of the cyclic carboxamide derivative represented by the general formula (1) is not particularly limited, and may be an inorganic salt or an organic salt.

[0035] The inorganic salt is not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include hydrochlorides, sulfates, phosphates, hydrobromides, sodium salts, potassium salts, magnesium salts, calcium salts, and ammonium salts.

[0036] The organic salt is not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include acetate, lactate, maleate, fumarate, tartrate, citrate, methanesulfonate, p-toluenesulfonate, triethanolamine salt, diethanolamine salt, and amino acid salt.

[0037] In the swelling-reducing agent according to one embodiment, the 1-(2-hydroxyethyl)-2-imidazolidinone or derivative thereof is a cyclic carboxamide derivative represented by general formula (1) or a salt thereof, and one type may be used alone, or two or more types may be used in combination.

[0038] 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof may be synthesized by a known method or may be a commercially available product.

[0039] The content of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof in the swelling-reducing agent according to one embodiment is not particularly limited and can be appropriately selected depending on the purpose, provided that it is an amount sufficient to effectively exert an swelling-reducing effect, but is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, even more preferably 0.01% by mass or more, even more preferably 0.1% by mass or more, and particularly preferably 1% by mass or more, relative to the total mass of the swelling-reducing agent. The upper limit of the content of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof in the swelling-reducing agent according to one embodiment is also not particularly limited, provided that it is an amount sufficient to effectively exert an swelling-reducing effect, and can be appropriately selected depending on the purpose, but is preferably 5% by mass or less, more preferably 4% by mass or less, even more preferably 3% by mass or less, even more preferably 2% by mass or less, and particularly preferably 1.5% by mass or less, relative to the total mass of the swelling-reducing agent. The lower and upper limits of the content of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof in the swelling-reducing agent according to one embodiment can be appropriately combined, and is preferably 0.0001% by mass to 5% by mass, more preferably 0.001% by mass to 4% by mass, even more preferably 0.01% by mass to 3% by mass, even more preferably 0.1% by mass to 2% by mass, and particularly preferably 1% by mass to 1.5% by mass, relative to the total mass of the swelling-reducing agent. When the swelling-reducing agent according to one embodiment contains two or more selected from 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof, the content of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof refers to the total content of the two or more 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof.

[0040] <Other Components> The anti-edema agent according to one embodiment may contain other components in addition to 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof, as long as the other components do not inhibit the anti-edema effect. Examples of other components include pharmacologically acceptable carriers or adjuvants such as diluents, binders, disintegrants, thickeners, dispersants, resorption promoters, flavoring agents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonicity agents, stabilizers, and pH adjusters. These may be used alone or in combination of two or more.

[0041] The content of other components in the anti-edema agent according to one embodiment is not particularly limited as long as the effect of reducing edema is not impaired, and can be appropriately selected depending on the purpose. Note that the anti-edema agent according to one embodiment may consist solely of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof.

[0042] [Administration method and dosage] The administration method and dosage of the swelling-reducing agent according to one embodiment are not particularly limited as long as they can achieve the swelling-reducing effect, and can be appropriately selected according to the purpose. Examples of the administration method include topical administration, oral administration, and parenteral administration (e.g., intravenous administration, intraperitoneal administration, etc.), but topical administration is preferred, and a method of applying to the skin is more preferred.

[0043] The swelling-reducing agent according to one embodiment can reduce swelling by preferably applying it to the skin. There are no particular limitations on the method of application and dosage when applying it to the skin, and they can be appropriately selected depending on the dosage form, the age, weight, and swelling state of the subject, but the method of application is preferably several times a day, more preferably once to five times a day. In this case, it may be rubbed directly into the skin, or it may be soaked into a base material such as gauze and then applied to the skin. The dosage is about 100mg / 10 .... ２ Preferably, the amount is 0.001 mL to 1 mL per unit volume.

[0044] [Dosage Form] The dosage form of the swelling-reducing agent according to one embodiment is not particularly limited and can be appropriately selected depending on the purpose. When used by topical administration as an external skin preparation, examples include solutions, solubilized systems, emulsions, powder dispersions, water-oil two-layer systems, water-oil-powder three-layer systems, ointments, creams, emulsions, lotions, gels, and aerosols. These dosage forms may also be impregnated into a substrate to form a patch. When used by oral administration, examples include solid preparations such as tablets, coated tablets, sugar-coated tablets, granules, powders, and capsules (e.g., hard and soft gelatin capsules); and liquid preparations (solutions, suspensions) such as oral liquids and syrups. When used by parenteral administration, examples include injections.

[0045] [Manufacturing Method] The manufacturing method of the anti-edema agent according to one embodiment is not particularly limited, and the agent can be manufactured by a method appropriately selected from known methods depending on the dosage form.

[0046] It should be noted that the scope of the present disclosure also includes use of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof for use in reducing swelling, and use of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof in the manufacture of an agent for reducing swelling.

[0047] (Cosmetic) The cosmetic according to one embodiment contains the anti-edema agent according to one embodiment, and further contains other ingredients as required.

[0048] <Anti-puffiness agent> The anti-puffiness agent contained in the cosmetic preparation according to one embodiment is as described above in the section (Anti-puffiness agent).

[0049] The content of the anti-puffiness agent in the cosmetic composition according to one embodiment is not particularly limited as long as it can exert an effect of reducing puffiness, and can be selected appropriately depending on the purpose.

[0050] <Other Components> The cosmetic according to one embodiment may contain other components in addition to the anti-puffiness agent. The other components are not particularly limited and can be appropriately selected from components typically incorporated into cosmetics depending on the form of the cosmetic, and examples include glycols, glycerins, sugar alcohols, sugars, oils, polymers, surfactants, powders, coloring materials, solvents, silicones, fragrances, drugs or medicinal ingredients other than the anti-puffiness agent, pH adjusters, sequestering agents, etc. These may be used alone or in combination of two or more.

[0051] <<Glycols>> Examples of glycols include propylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, diethylene glycol, triethylene glycol, and polyethylene glycol.

[0052] <<Glycerins>> Examples of glycerins include glycerin, diglycerin, and polyglycerin.

[0053] <<Sugar Alcohols>> Examples of sugar alcohols include sorbitol, mannitol, maltitol, xylitol, and erythritol.

[0054] <<Sugars>> Examples of sugars include fructose, glucose, galactose, maltose, lactose, and trehalose.

[0055] <<Oil>> Examples of oils include fats and oils, waxes, hydrocarbon oils, higher fatty acids, higher alcohols, ester oils, silicone oils, oil-soluble drugs, etc. These may be used alone or in combination of two or more.

[0056] - Fats and Oils - Examples of fats and oils include vegetable fats and oils such as avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, sesame oil, persic oil, wheat germ oil, camellia oil, castor oil, linseed oil, safflower oil, cottonseed oil, perilla oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, Chinese tung oil, Japanese tung oil, jojoba oil, germ oil, cacao butter, coconut oil, hardened coconut oil, palm oil, palm kernel oil, and Japan wax kernel oil; and animal fats and oils such as egg yolk oil, horse tallow, beef tallow, mutton tallow, hardened beef tallow, lard, beef bone fat, and beef leg fat.

[0057] - Waxes - Examples of waxes include Japan wax, beeswax, candelilla wax, cotton wax, carnauba wax, bayberry wax, privet wax, whale wax, montan wax, rice bran wax, lanolin, kapok wax, lanolin acetate, liquid lanolin, sugarcane wax, lanolin fatty acid isopropyl, hexyl laurate, reduced lanolin, jojoba wax, hard lanolin, and shellac wax.

[0058] Hydrocarbon Oils Examples of hydrocarbon oils include linear, branched, and volatile hydrocarbon oils. Specific examples of hydrocarbon oils include liquid paraffin, squalane, isoparaffin, α-olefin oligomers, polybutene, microcrystalline wax, and hydrogenated polydecene.

[0059] -Higher Fatty Acids- Examples of higher fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, 12-hydroxystearic acid, undecylenic acid, lanolin fatty acid, isostearic acid, linoleic acid, linolenic acid, and eicosapentaenoic acid.

[0060] —Higher Alcohols— Examples of higher alcohols include alcohols having 6 or more carbon atoms. Specific examples of higher alcohols include straight-chain or branched-chain higher alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, behenyl alcohol, myristyl alcohol, oleyl alcohol, cetostearyl alcohol, monostearyl glycerin ether (batyl alcohol), 2-decyltetradecynol, 2-octyldodecanol, lanolin alcohol, cholesterol, phytosterol, hexyldodecanol, isostearyl alcohol, and octyldodecanol.

[0061] - Ester Oil - Examples of ester oils include glycerin triisooctanoate, glycerin triisopalmitate, octyl isopalmitate, isopropyl isostearate, isostearyl isostearate, isocetyl isostearate, hexyl isostearate, myristyl isostearate, isocetyl octanoate, cetyl isooctanoate, isostearyl octanoate, isodecyl isononanoate, octyldodecyl dimethyloctanoate, oleyl myristate, isostearyl erucate, isocetyl stearate, octyl stearate, isostearyl palmitate, isocetyl palmitate, palmitic acid ... Examples of the hydroxybenzoates include octyl myristate, isostearyl myristate, isocetyl myristate, octyldodecyl myristate, decyl myristate, isopropyl palmitate, isopropyl myristate, trimethylolpropane triisostearate, neopentyl glycol dicaprate, dioctyl sebacate, octyldodecyl 12-stearoyloxystearate, dioctyldodecyl stearoyl glutamate, dioctyl adipate, diisostearyl malate, octyl methoxycinnamate, octyldodecyl lactate, isostearyl lactate, and octyl paradimethylaminobenzoate.

[0062] Silicone Oil Examples of silicone oil include volatile cyclic silicone, volatile dimethylpolysiloxane, and methylphenylsilicone.

[0063] -Oil-soluble drugs- Examples of oil-soluble drugs include fat-soluble vitamins such as vitamin A, retinol, retinol acetate, retinol palmitate, benzyl nicotinate, dl-α-tocopherol nicotinate, vitamin D2, and tocopherol.

[0064] <<Polymers>> Examples of polymers include plant-based polymers, animal-based polymers, microbial-based polymers, starch-based polymers, cellulose-based polymers, alginic acid-based polymers, vinyl-based polymers, acrylic polymers, inorganic water-soluble polymers, etc. These polymers may act as thickeners.

[0065] Examples of plant-derived polymers include gum arabic, tragacanth gum, galactan, guar gum, carob gum, karaya gum, gellan gum, carrageenan, pectin, and agar.

[0066] Examples of animal-derived polymers include collagen, casein, albumin, and gelatin.

[0067] Examples of microbial polymers include xanthan gum, dextran, succinoglucan, and pullulan.

[0068] Examples of starch-based polymers include vegetable starches such as those from corn, wheat, potato, and rice; carboxymethyl starch; and methylhydroxypropyl starch.

[0069] Examples of the cellulose polymer include methyl cellulose, nitrocellulose, ethyl cellulose, methylhydroxypropyl cellulose, hydroxyethyl cellulose, sodium cellulose sulfate, hydroxypropyl cellulose, sodium carboxymethyl cellulose, and crystalline cellulose.

[0070] Examples of alginic acid polymers include sodium alginate and propylene glycol alginate.

[0071] Examples of vinyl polymers include polyvinyl alcohol, polyvinyl acetate, polyvinyl methyl ether, polyvinyl pyrrolidone, copolymers of vinyl pyrrolidone and vinyl acetate, and carboxyvinyl polymers.

[0072] Examples of acrylic polymers include sodium polyacrylate, polyethyl acrylate, alkanolamine polyacrylate, copolymers of alkyl methacrylate and dimethylaminoethyl methacrylate, poly 2-acrylamido-2-methylpropanesulfonic acid, and polymethacryloyloxytrimethylammonium.

[0073] Examples of inorganic water-soluble polymers include polyethyleneimine, cationic polymers, bentonite, aluminum magnesium silicate, laponite, hectorite, and silicic anhydride.

[0074] <<Surfactant>> Examples of surfactants include anionic surfactants, cationic surfactants, nonionic surfactants, and amphoteric surfactants.

[0075] Examples of anionic surfactants include fatty acid soaps such as soap bases, sodium laurate, and sodium palmitate; higher alkyl sulfates such as sodium lauryl sulfate and potassium lauryl sulfate; alkyl ether sulfates such as polyoxyethylene (hereinafter sometimes abbreviated as "POE") triethanolamine lauryl sulfate and sodium POE lauryl sulfate; N-acylsarcosinates such as sodium lauroyl sarcosinate; higher fatty acid amide sulfonic acids such as sodium N-myristoyl-N-methyl taurate and sodium coconut oil fatty acid methyl tauride; phosphate ester salts such as POE stearyl ether phosphate; monolauroyl monoethanolamide POE sodium sulfosuccinate, lauryl polypropylene alkylbenzenesulfonates such as sodium glycol sulfosuccinate; alkylbenzenesulfonates such as sodium linear dodecylbenzenesulfonate and triethanolamine linear dodecylbenzenesulfonate; N-acylglutamates such as disodium N-stearoylglutamate and monosodium N-stearoylglutamate; higher fatty acid ester sulfates such as hydrogenated coconut oil fatty acid glycerin sodium sulfate; sulfated oils such as turmeric oil; POE alkyl ether carboxylic acids; POE alkyl allyl ether carboxylates; higher fatty acid ester sulfonates; secondary alcohol sulfates; higher fatty acid alkylolamide sulfates; sodium lauroyl monoethanolamide succinate; and sodium caseinate.

[0076] Examples of cationic surfactants include alkyltrimethylammonium salts such as stearyltrimethylammonium chloride and lauryltrimethylammonium chloride; dialkyldimethylammonium salts such as distearyldimethylammonium chloride; alkylpyridinium salts such as cetylpyridinium chloride; alkyl quaternary ammonium salts; alkyldimethylbenzylammonium salts; alkylisoquinolinium salts; dialkylmorphonium salts; POE alkylamines; alkylamine salts; polyamine fatty acid derivatives; amyl alcohol fatty acid derivatives; and benzalkonium chloride.

[0077] Examples of nonionic surfactants include lipophilic nonionic surfactants, hydrophilic nonionic surfactants, etc. Examples of lipophilic nonionic surfactants include sorbitan fatty acid esters such as sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, and sorbitan trioleate; glycerin polyglycerin fatty acids such as glycerin monocottonseed oil fatty acid, glycerin monostearate, glycerin sesquioleate, and glycerin monostearate malate; propylene glycol fatty acid esters such as propylene glycol monostearate; glycerin alkyl ethers; and POE-methylpolysiloxane copolymers. Examples of hydrophilic nonionic surfactants include POE sorbitan fatty acid esters such as POE sorbitan monooleate and POE sorbitan monostearate; POE sorbit fatty acid esters such as POE sorbit monolaurate, POE sorbit monooleate and POE sorbit monostearate; POE glycerin fatty acid esters such as POE glycerin monooleate and POE glycerin distearate; POE fatty acid esters such as POE monooleate, POE distearate and POE monodioleate; POE alkyl ethers such as POE lauryl ether, POE oleyl ether and POE cholestanol ester; POE Examples of suitable POE alkyl phenyl ethers include POE octylphenyl ether and POE nonylphenyl ether; POE polyoxypropylene (hereinafter sometimes abbreviated as "POP") monobutyl ether, POE POP cetyl ether, and POE POP glycerin ether; POE beeswax and lanolin derivatives such as POE sorbitol beeswax; alkanolamides such as coconut oil fatty acid diethanolamide and fatty acid isopropanolamide; POE propylene glycol fatty acid esters; POE fatty acid amides, POE alkylamines; sucrose fatty acid esters, and alkylethoxydimethylamine oxides.

[0078] Examples of amphoteric surfactants include imidazoline-based amphoteric surfactants such as 2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt; and betaine-based surfactants such as amidobetaine and sulfobetaine.

[0079] <<Powder>> The powder may be an inorganic powder or an organic powder.

[0080] Examples of inorganic powders include mica, talc, kaolin, sericite (sericite), muscovite, phlogopite, synthetic mica, lepidolite, biotite, lepidolite, synthetic mica, anhydrous silicic acid (silica), aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, aluminum oxide, barium sulfate, zeolite, titanium oxide, zinc oxide, and boron nitride.

[0081] Examples of organic powders include polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, calcium carbonate powder, magnesium carbonate powder, styrene-acrylic acid copolymer resin powder, and cellulose powder.

[0082] <<Coloring Material>> Examples of the coloring material include pigments and dyes.

[0083] Pigments Examples of pigments include inorganic pigments, organic pigments, pearl pigments, and metal powder pigments.

[0084] Examples of inorganic pigments include inorganic white pigments such as titanium dioxide and zinc oxide; inorganic red pigments such as iron oxide (red iron oxide); inorganic yellow pigments such as yellow iron oxide and yellow ochre; black pigments such as black iron oxide and carbon black; inorganic green pigments such as chromium oxide, chromium hydroxide and cobalt titanate; and inorganic blue pigments such as ultramarine and iron blue.

[0085] Examples of organic pigments include Red No. 3, Red No. 104, Red No. 106, Red No. 201, Red No. 202, Red No. 204, Red No. 205, Red No. 220, Red No. 226, Red No. 227, Red No. 228, Red No. 230, Red No. 401, Red No. 405, Red No. 505, Orange No. 203, Orange No. 204, Orange No. 205, Yellow No. 4, Yellow No. 5, Yellow No. 202, Yellow No. 203, Yellow No. 205, Yellow No. 401, Blue No. 1, Blue No. 404, Green No. 3, and zirconium lakes, barium lakes, or aluminum lakes thereof.

[0086] Examples of pearl pigments include titanium oxide coated mica, colored titanium oxide coated mica, bismuth oxychloride, and fish scale foil.

[0087] Examples of metal powder pigments include aluminum powder and copper powder.

[0088] - Pigments - Examples of pigments include natural pigments such as chlorophyll and β-carotene.

[0089] <<Solvent>> Examples of the solvent include water and lower alcohols. Examples of the lower alcohol include alcohols having 5 or fewer carbon atoms. Specific examples of the lower alcohol include methanol, ethanol, propyl alcohol, isopropyl alcohol, 2-amino-2-methyl-1-propanol, and 2-amino-2-methyl-1,3-propanediol.

[0090] <<Silicones>> The silicones are not particularly limited and can be appropriately selected depending on the purpose. Examples thereof include linear silicones, cyclic silicones, and modified silicones.

[0091] Examples of the chain silicone include dimethylpolysiloxane (dimethicone), methylphenylpolysiloxane (phenylmethicone), and methylhydrogenpolysiloxane.

[0092] Examples of cyclic silicones include octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane.

[0093] Examples of modified silicones include amino-modified silicone oil, polyether-modified silicone oil, carboxy-modified silicone oil, alkyl-modified silicone oil, ammonium salt-modified silicone oil, and fluorine-modified silicone oil.

[0094] These silicones may be used alone or in combination of two or more.

[0095] <<Drug or Medicinal Ingredient>> The drug is not particularly limited as long as it is a drug or medicinal ingredient other than an anti-edema agent, and examples include vitamins, ultraviolet absorbers, chelating agents, preservatives, plant extracts, moisturizers, anti-inflammatory agents, whitening agents, cooling agents, amino acids, antioxidants, disinfectants, and various skin nutrients.

[0096] Vitamins Examples of vitamins include water-soluble vitamins such as vitamin B6 hydrochloride, pantothenyl ethyl ether, pyridoxine hydrochloride, nicotinamide, pantothenic acid, and biotin.

[0097] -Ultraviolet Absorber- Examples of the ultraviolet absorber include benzoic acid-based ultraviolet absorbers such as para-aminobenzoic acid; anthranilic acid-based ultraviolet absorbers such as methyl anthranilate; salicylic acid-based ultraviolet absorbers such as octyl salicylate; cinnamic acid-based ultraviolet absorbers such as isopropyl paramethoxycinnamate and octyl paramethoxycinnamate; ultraviolet absorbers such as urocanic acid and ethyl urocanate, benzophenone-based ultraviolet absorbers such as 2-hydroxy-4-methoxybenzophenone and dihydroxybenzophenone, benzotriazole-based ultraviolet absorbers, and 2-phenylbenzimidazole-5-sulfonic acid.

[0098] -Chelating Agent- Examples of the chelating agent include citramalic acid, agaric acid, glyceric acid, shikimic acid, hinokitiol, gallic acid, tannic acid, caffeic acid, ethylenediamine-N,N,N',N'-tetraacetic acid disodium salt dihydrate (EDTA-2Na-2H２ O ２ ), ethylene glycol diamine tetraacetic acid, diethylene triamine pentaacetic acid, phytic acid, polyphosphoric acid, metaphosphoric acid, analogs thereof, alkali metal salts thereof, carboxylic acid esters thereof, and the like.

[0099] - Preservatives - Examples of preservatives include benzoic acid, salicylic acid, paraoxybenzoic acid esters (e.g., methylparaben, ethylparaben, butylparaben, etc.), sorbic acid, parachlormetacresol, hexachlorophene, benzalkonium chloride, chlorhexidine chloride, trichlorocarbanilide, photosensitizers, phenoxyethanol, and chlorphenesin.

[0100] -Plant Extracts- Examples of plant extracts include houttuynia cordata extract, phellodendron bark extract, licorice extract, peony extract, moutan extract, loofah extract, saxifrage extract, eucalyptus extract, clove extract, horse chestnut extract, cornflower extract, seaweed extract, thyme extract, etc. These plant extracts may also contain caffeine, tannins, etc.

[0101] - Moisturizing Agent - Examples of moisturizing agents include polyethylene glycol (hereinafter sometimes abbreviated as "PEG"), sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, glucosamine, cyclodextrin, etc. In addition, the glycols, glycerins, sugar alcohols, and sugars can also be used as moisturizing agents.

[0102] Anti-inflammatory Agents Anti-inflammatory agents include, for example, azulene, glycyrrhizin, lysozyme chloride, pyridoxine hydrochloride, sulfur, and the like.

[0103] - Whitening Agents - Examples of whitening agents include arbutin, 4-methoxysalicylic acid, tranexamic acid, vitamin C, ethyl vitamin C, magnesium ascorbyl phosphate, ascorbic acid glucoside, and kojic acid.

[0104] - Cooling Agents - Examples of cooling agents include L-menthol and camphor.

[0105] -Antioxidants- Examples of antioxidants include ascorbic acid, α-tocopherol, and carotenoids.

[0106] <<pH Adjuster>> Examples of pH adjusters include potassium hydroxide, sodium hydroxide, triethanolamine, sodium carbonate, lactic acid, citric acid, sodium citrate, glycolic acid, succinic acid, tartaric acid, malic acid, sodium bicarbonate, and ammonium bicarbonate.

[0107] <<Sequestering Agent>> Examples of sequestering agents include disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid.

[0108] In the cosmetic according to one embodiment, the content of other ingredients is not particularly limited as long as it does not impair the effect of the cosmetic according to one embodiment, and can be selected appropriately depending on the purpose.

[0109] [Uses] The uses of the cosmetic according to one embodiment are not particularly limited and can be appropriately selected depending on the purpose. Examples include lotion, emulsion, cream, essence, jelly, gel, ointment, pack, mask, and foundation.

[0110] The following examples, comparative examples, and test examples will be used to explain the embodiments in more detail, but the embodiments are not limited to these examples, comparative examples, and test examples. In the examples and comparative examples shown in Table 1 below, the blending amounts are expressed in "% by mass" relative to the total mass of the lotion.

[0111] Example 1 A lotion having the composition and blending amount shown in Table 1 below was prepared by a conventional method.

[0112] Comparative Example 1 A lotion having the composition and blending amount shown in Table 1 below was prepared by a conventional method.

[0113]

[0114] (Test Example 1) Thirty-nine healthy Japanese female panelists in their 20s to 60s were asked to apply 0.3 mL of the lotion of Example 1 to half of their faces twice a day, in the morning and evening. The left and right half of the face were randomly assigned, with 19 panelists applying the lotion of Example 1 to the right side of the midline of their faces and 20 panelists applying it to the left side of their faces. The half of the face to which the lotion of Example 1 was applied was designated the "Q half face." Next, the same panelists were asked to apply 0.3 mL of the lotion of Comparative Example 1 to the half of their faces opposite the side to which the lotion of Example 1 was applied, twice a day, in the morning and evening. The half of the face opposite the side to which the lotion of Example 1 was applied means, for example, that for a panelist who applied the lotion of Example 1 to the left side of their faces, the lotion of Comparative Example 1 was applied to the right side of their faces. The half of the face to which the lotion of Comparative Example 1 was applied was designated the "P half face." The lotions of Example 1 and Comparative Example 1 were applied for 6 weeks. The compositions of the lotions of Example 1 and Comparative Example 1 were not disclosed to the panelists. Next, the following visual evaluation and quantitative evaluation were carried out.

[0115] <Visual Evaluation> For the half face (half face Q) to which the lotion of Example 1 was applied and the half face (half face P) to which the lotion of Comparative Example 1 was applied, photographs of the left and right faces were taken with a digital camera at a 45-degree angle from the front, with the midline of the face facing forward. Using a pair of left and right facial photographs, four expert evaluators each performed a visual evaluation of "which of the left and right faces appeared more swollen." Figure 3A is a schematic diagram of a pair of left and right facial photographs. The visual evaluation was performed without disclosing to the expert evaluators which half of the face each of the lotions of Example 1 and Comparative Example 1 had been applied.

[0116] The evaluation was carried out before the first application of the lotions of Example 1 and Comparative Example 1 (hereinafter referred to as "week 0"), and 3 and 6 weeks after the start of application of the lotions of Example 1 and Comparative Example 1. For the evaluation of each week, four expert evaluators each performed five evaluations. The evaluation was carried out based on the following evaluation criteria. Each expert evaluator's score was assigned to the Q half face and the P half face, and for each week's evaluation, an average value a of the scores of the five evaluations for each expert evaluator was calculated for each panelist. Next, an average value b of the average value a for the 39 panelists at week 0, 3 weeks, and 6 weeks was calculated. Next, an average value c of the average value b for the four expert evaluators was calculated. The standard error of the average value b was also calculated. - Evaluation criteria - Rating -1 point: The Q half face looks swollen Rating 1 point: The P half face looks swollen

[0117] The results are shown in Figure 3B. In Figure 3B, "*" indicates a significant difference, with a p-value of 0.013 based on a paired T-test (two-tailed T-test) between before application (week 0) and 6 weeks after the start of application. Before application (week 0), there was no difference between the P half-face and the Q half-face. On the other hand, 6 weeks after the start of application, the P half-face appeared significantly more swollen, in other words, the Q half-face appeared less swollen.

[0118] <Quantitative Evaluation> Before the first application of the lotions of Example 1 and Comparative Example 1 (week 0), and 3 and 6 weeks after the start of application of the lotions of Example 1 and Comparative Example 1, data representing the three-dimensional shape of the panelists' faces (three-dimensional shape facial images) were taken using a 3D image capture and analysis device (VECTRA Handy H2 (VEC-H2, manufactured by Canfield Scientific). At this time, three-dimensional shape facial images were obtained when the panelists' faces were in a horizontal position (specifically, when the midline of the face was held still at a right angle to the direction of gravity) and when the panelists' faces were in a vertical position (specifically, when the midline of the face was held still parallel to the direction of gravity). Next, the three-dimensional shape facial images when the panelists' faces were in a horizontal position were calculated using a computer. Based on the change in three-dimensional shape between the image of the face in the upright position and the image of the face in the upright position, the amount of gravitational swelling (VCswelling) and the amount of gravitational depression (VCshrinking) were calculated for each of the half face to which the lotion of Example 1 was applied (half face Q) and the half face to which the lotion of Comparative Example 1 was applied (half face P). Next, the amount of facial swelling (Sc) was calculated based on the amount of gravitational swelling (VCswelling) and the amount of gravitational depression (VCshrinking).

[0119] - Calculation of the amount of facial swelling (Sc) - The amount of facial swelling (Sc) was calculated using the following formula (1): Three-dimensional facial images were obtained three times for each panelist at 0 weeks, 3 weeks, and 6 weeks, and the average value was used as the amount of facial swelling (Sc) for that panelist.

[0120] (Note that in formula (1), "Sc" represents the amount of facial swelling, "VCswelling" represents the amount of gravitational swelling, and "VCshrinking" represents the amount of gravitational depression.)

[0121] Next, the improvement in the amount of facial swelling (Sc) was calculated using the following formulas (3) and (4).

[0122] Difference in the amount of facial swelling (Sc) between the left and right sides = [Q amount of swelling of half face (Sc)] - [P amount of swelling of half face (Sc)] ... Formula (3) Improvement in the amount of facial swelling (Sc) = [difference in the amount of facial swelling (Sc) between the left and right sides at week 0] - [difference in the amount of facial swelling (Sc) after n weeks] ... Formula (4) (where n = 3 or 6 in Formula (4))

[0123] A graph showing the change in the amount of improvement in facial swelling (Sc) from week 0 to week 6 after the start of the test is shown in Figure 4. In Figure 4, "*" indicates p<0.05. From these results, the p-values ​​for week 0 and week 6 were less than 0.05, and the amount of swelling (Sc) of half face Q to which the lotion of Example 1 was applied was significantly improved compared to half face P to which the lotion of Comparative Example 1 was applied.

[0124] The results of Test Examples 1 and 2 demonstrate that an anti-edema agent containing 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient has an excellent anti-edema effect.

[0125] Examples of aspects of the present invention include the following. <1> An anti-edema agent characterized by containing 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient. <2> The anti-edema agent according to <1>, wherein the 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof contains, as an active ingredient, a cyclic carboxamide derivative represented by the following general formula (1) or a salt thereof: (In the general formula (1), n ​​represents an integer of 1 to 3, and R １ represents a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydrogen atom or a hydroxyl group, and X represents -CH ２ - or -N(R ２ )-, and R ２represents a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydrogen atom or a hydroxyl group.) <3> The anti-edema agent according to <1> or <2> above, which is an external preparation for skin. <4> A cosmetic preparation containing the anti-edema agent according to any one of <1> to <3> above. <5> 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof for use in reducing edema. <6> Use of 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof in the manufacture of an anti-edema agent.

[0126] As described above, the present invention has been described based on specific embodiments and examples, but these embodiments and examples are presented merely as examples, and the present invention is not limited to the above embodiments and examples. The above embodiments can be embodied in various other forms, and various combinations, omissions, substitutions, additions, modifications, etc. can be made without departing from the spirit of the invention. These embodiments and their modifications are included in the scope and spirit of the invention, and are also included in the inventions described in the claims and their equivalents.

[0127] This international application claims priority based on Japanese Patent Application No. 2023-220018, filed on December 26, 2023, the entire contents of which are incorporated herein by reference.

Claims

1. An agent for improving swelling, characterized by containing 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof as an active ingredient.

2. The puffiness improver according to claim 1, wherein the 1-(2-hydroxyethyl)-2-imidazolidinone or its derivative contains, as an active ingredient, a cyclic carboxamide derivative represented by the following general formula (1) or a salt thereof. (However, in the general formula (1), n represents an integer of 1 to 3, and R １ represents a hydrogen atom or a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group, and X represents -CH ２ - or a group represented by -N(R ２ ), and R ２ represents a hydrogen atom or a hydrocarbon group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group.) 3. The agent for improving swelling according to claim 1, which is a topical skin preparation.

4. A cosmetic characterized by containing the agent for improving swelling according to claim 1.

Images